TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a…
VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:…
September 18, 2025 16:30 ET | Source: NovaBay Pharmaceuticals Inc. EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals,…
September 17, 2025 16:02 ET | Source: Aeluma, Inc. GOLETA, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Aeluma, Inc. (NASDAQ:…
September 12, 2025 16:30 ET | Source: Fulcrum Therapeutics, Inc. CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics,…
The landmark multiomics study will examine how lifestyle, environmental, socioeconomic, and genetic factors play a significant role in shaping common…
BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical…
BEIJING, Sept. 9, 2025 /PRNewswire/ -- A news report from China Daily: The Shanghai Cooperation Organization (SCO), guided by the…
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi companyKER-0193, a novel, orally bioavailable…
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…